Little by little we are leaving behind the coronavirus pandemic. Our day-to-day looks more and more like the dates prior to March 2020, but that does not mean that COVID-19 has disappeared from our lives. Science and health authorities continue to monitor the virus and the disease, research continues and the alert to a potential appearance of new variants that infections among the population increase again.
To stop these new variants, vaccines are key, which have helped so much to mitigate the impact that the pandemic has caused in society. In this sense it is key that the long-awaited vaccines adapted to the new variants arrive (especially Omicron), in order to stop the spread of the virus.
In this sense, the European Medicines Agency (EMA, for its acronym in English), has given good news about the date on which these vaccines could see the light. According to the agency, thes first vaccines adapted to the new variants “could be approved in September”, a highly anticipated situation and that it affirms will be the same throughout the world. In other words, drug regulators want to approve these vaccines in a harmonized way so that these new doses are available throughout the planet.
New vaccines and doses for children
Likewise, the EMA has taken the opportunity to report that the Moderna vaccine is being evaluated for use in children between 6 months and 5 years of age, as well as the Pfizer kids booster dose in ages between 5 and 11 years.
In addition, the European agency is also currently studying the reports submitted by Valneva y Sanofi-Pasteuras well as the booster dose of the vaccine Novavax.
AstraZeneca treatment against coronavirus
Lastly, regarding treatments, the EMA has announced that AstraZeneca’s, Evusheldcurrently recommended only for the prevention of coronavirus, “data could be presented” so that in the future it is treatment of COVID in patients at risk of developing severe disease.
–
